|
|
Pilot Study of Mutant Ras Peptide-Based Vaccine as an Adjuvant
Treatment in Pancreatic and Colorectal Cancers.
Toubaji A, Achtar M,
Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S,
Venzon D, Gause B, Marincola F, Khleif SN.
Cancer Immunol Immunother. [Epub] 2008 Feb 23. Vaccine Branch,
NCI, NIH, NNMC, Bethesda, Maryland.
[Link
to Abstract]
Treatment with Combined Streptozotocin
and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic
Tumors.
Fjällskog ML, Janson
ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK.
Neuroendocrinology. [Epub] 2008 Feb 18. Uppsala University, Sweden.
[Link
to Abstract]
JANUARY
Irinotecan Plus Gemcitabine
and 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase II
Study.
Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth
H, Grossmann J, Schlottmann K, Kullmann F.
Oncology. 2007;72(5-6):279-84. Epub 2008 Jan 11. University of
Regensburg, Germany.
[Link
to Abstract]
Neoadjuvant Chemoradiation
in Patients with Potentially Resectable Pancreatic Cancer.
Takai S, Satoi S, Yanagimoto
H, Toyokawa H, Takahashi K, Terakawa N, Araki H, Matsui Y, Sohgawa
M, Kamiyama Y.
Pancreas. 2008 Jan;36(1):e26-32. Kansai Medical University, Hirakata-City,
Osaka, Japan.
[Link
to Abstract]
A Phase II Study of Capecitabine Plus Gemcitabine in Patients
with Locally Advanced or Metastatic Pancreatic Cancer.
Song HS, Do YR, Chang
HM, Ryu MH, Lee KH, Kim YH, Hong DS, Cho JY, Lee KE, Kim SY.
Cancer Chemother Pharmacol. Epub 2008 Jan 3. Dongsan Medical
Center, Keimyung University School of Medicine, Dongsan-Dong,
Chung-Gu, Daegu, South Korea.
[Link
to Abstract]
Preoperative Chemoradiation
in Adenocarcinoma of the Pancreas. A Single Centre Experience
Advocating a New Treatment Strategy.
Golcher H, Brunner T,
Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, Meyer
T.
Eur J Surg Oncol. Epub 2008 Jan 9. University of Erlangen, Germany.
[Link
to Abstract]
2007
DECEMBER
3D Radiotherapy Can Be Safely
Combined with Sandwich Systemic Gemcitabine Chemotherapy in the
Management of Pancreatic Cancer: Factors Influencing Outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham
P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta
B, Goldstein D.
Int J Radiat Oncol Biol Phys., Epub: Dec 28, 2007. Sir Charles
Gairdner Hospital, Nedlands, WA, Australia.
[Link
to Abstract]
Clinical Efficacy of Intra-Arterial
Pharmacokinetic Chemotherapy with 5-Fluorouracil, CDDP, Gemcitabine,
and Angiotensin-II in Patients with Advanced Pancreatic Cancer.
Ishikawa T, Kamimura
H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida
T, Takeda K, Kamimura T.
Hepatogastroenterology. 2007 Dec;54(80):2378-82. Saiseikai Niigata
Second Hospital, Niigata, Japan.
[Link
to Abstract]
Erlotinib/Gemcitabine for
First-Line Treatment of Locally Advanced Or Metastatic Adenocarcinoma
of the Pancreas.
Senderowicz AM, Johnson
JR, Sridhara R, Zimmerman P, Justice R, Pazdur R.
Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion
1706-9, 1712, 1715. Office of Oncology Drug Products, Center
for Drug Evaluation and Research, US Food and Drug Administration,
Silver Spring, Maryland.
[Link
to Abstract]
Use of Octreotide for the
Prevention of Pancreatic Fistula After Elective Pancreatic Surgery:
A Systematic Review and Meta-Analysis.
Alghamdi AA, Jawas AM,
Hart RS.
Can J Surg. 2007 Dec;50(6):459-66. University of Toronto, Ontario,
Canada.
[Link
to Abstract]
NOVEMBER
Capecitabine in Combination
with Docetaxel and Mitomycin C in Patients with Pre-Treated Tumours:
Results of an Extended Phase-I Trial.
Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B,
Hochhaus A, Hofheinz RD.
Br J Cancer. 2007 Dec 3;97(11):1475-9; Epub 2007 Nov 13. Medizinische
Fakultät Mannheim der Universität Heidelberg, Germany.
[Link to Abstract]
Long-Term Survival on Capecitabine
in Two Gemcitabine Refractory Pancreatic Cancer Patients. Is
There a Pharmacogenetic Explanation?
Saif MW, Kang SP, Ledbetter
L, Steg A, Diasio R, Johnson M.
JOP. 2007 Nov 9;8(6):799-805. Yale University School of Medicine.
New Haven, Connecticut; University of Alabama at Birmingham,
Alabama.
[Link to Abstract]
Poxvirus-Based Vaccine Therapy
for Patients with Advanced Pancreatic Cancer.
Kaufman HL, Kim-Schulze
S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall
J.
J Transl Med. 2007 Nov 26;5:60. Division of Surgical Oncology,
Columbia University, New York.
[Link
to Abstract]
Transarterial Chemoperfusion
with Gemcitabine and Mitomycin C in Pancreatic Carcinoma: Results
in Locally Recurrent Tumors and Advanced Tumor Stages.
Vogl TJ, Zangos S, Heller
M, Hammerstingl RM, Böcher E, Jacob U, Bauer RW.
Rofo. 2007 Nov;179(11):1181-8. Institut für Diagnostische
und Interventionelle Radiologie, J. W. Goethe-Universität
Frankfurt, Germany.
[Link
to Abstract]
OCTOBER
Phase I and Pharmacokinetic
Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients
with Refractory Solid Tumors.
Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF,
Egorin MJ, Rubin EH, Poplin EA.
Clin Cancer Res. 2007 Oct 1;13(19):5876-82. The Cancer Institute
of New Jersey, University of Medicine & Dentistry of New
Jersey, Robert Wood Johnson Medical School, New Brunswick, New
Jersey.
[Link to Abstract]
Phase I Dose-Finding Study
of Weekly Docetaxel Followed by Flavopiridol for Patients with
Advanced Solid Tumors.
Fornier MN, Rathkopf
D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R,
Kelsen DP, Schwartz GK.
Clin Cancer Res. 2007 Oct 1;13(19):5841-6. Memorial Sloan-Kettering
Cancer Center, New York.
[Link to Abstract]
Phase I Study of Oxaliplatin,
Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic
Cancer.
Desai SP, Ben-Josef E,
Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti
LM, Lawrence TS, Zalupski MM.
J Clin Oncol. 2007 Oct 10;25(29):4587-92. University of Michigan,
Ann Arbor.
[Link to Abstract]
Capecitabine Plus Erlotinib
in Gemcitabine-Refractory Advanced Pancreatic Cancer.
Kulke MH, Blaszkowsky
LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak
EL, Muzikansky A, Lawrence C, Fuchs CS.
J Clin Oncol. 2007 Oct 20;25(30):4787-92. Dana-Farber Cancer
Institute, Boston, Massachusetts.
[Link to Abstract]
SEPTEMBER
Complete Remission of a Metastatic
Pancreatic Carcinoma after Modified G-FLIP Therapy.
Alldinger I, Tsamaloukas
AG, Germing U, Hosch SB, Knoefel WT.
Chemotherapy. 2007;53(5):356-9.Epub 2007 Sep 3. University Hospital
Dusseldorf, Germany.
[Link to Abstract]
Curcumin Augments Gemcitabine
Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines.
Lev-Ari S, Vexler A,
Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, Ben-Yosef R.
Cancer Invest. 2007 Sep;25(6):411-8. Tel-Aviv University, Israel.
[Link to Abstract]
Efficacy of Preoperative Radiochemotherapy
in Patients with Locally Advanced Pancreatic Carcinoma.
Lind PA, Isaksson B,
Almström M, Johnsson A, Albiin N, Byström P, Permert
J.
Acta Oncol. Epub 2007 Sep 20;:1-8. Karolinska-Stockholm Söder
Hospital, Stockholm, Sweden.
[Link to Abstract]
Neoadjuvant Chemotherapy and
Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma:
Feasibility, Efficacy, and Survival.
Allendorf JD, Lauerman
M, Bill A, Digiorgi M, Goetz N, Vakiani E, Remotti H, Schrope
B, Sherman W, Hall M, Fine RL, Chabot JA.
J Gastrointest Surg. Epub 2007 Sep 5. Columbia University College
of Physicians and Surgeons, New York.
[Link to Abstract]
A Phase I Study of Erlotinib
in Combination with Gemcitabine and Radiation in Locally Advanced,
Non-Operable Pancreatic Adenocarcinoma.
Duffy A, Kortmansky J,
Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP,
O'reilly EM.
Ann Oncol. Epub 2007 Sep 17. Memorial Sloan-Kettering Cancer
Center, New York.
[Link to Abstract]
AUGUST
Arterial Infusion of 5-Fluorouracil
Combined with Concurrent Radiotherapy for Unresectable Pancreatic
Cancer: Results From a Pilot Study.
Tanaka T, Sakaguchi H,
Anai H, Yamamoto K, Morimoto K, Tamamoto T, Kichikawa K.
AJR Am J Roentgenol. 2007 Aug;189(2):421-8. Nara Medical University,
Kashihara, Japan.
[Link to Abstract]
Effect of Low-Molecular-Weight
Heparin on Survival in Patients with Advanced Pancreatic Adenocarcinoma.
von Delius S, Ayvaz M,
Wagenpfeil S, Eckel F, Schmid RM, Lersch C.
Thromb Haemost. 2007 Aug;98(2):434-9. Technical University of
Munich, Germany.
[Link to Abstract]
Meta-Analysis on Gemcitabine
of Fixed-Dose Rate Infusion Plus Oxaliplatin as First-Line Therapy
for Advanced Pancreatic Cancer.
Xie DR, Liang HL, Yang
Q, Guo SS, Jiang ZM.
Ai Zheng. 2007 Aug;26(8):895-9. The Second Affiliated Hospital,
Sun Yat-sen University, Guangzhou, Guangdong, China.
[Link to Abstract]
Phase I Trial of Fixed Dose
Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic
Carcinoma.
Carneiro BA, Brand RE,
Fine E, Knop RH, Khandekar JD, Uhlig W, Locker GY.
Cancer Invest. 2007 Aug;25(5):366-71. Kellogg Cancer Care Center,
Evanston Northwestern Healthcare, Evanston, Illinois.
[Link to Abstract]
JULY
Correlation Between Development
of Rash and Efficacy in Patients Treated with the Epidermal Growth
Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large
Phase III Studies.
Wacker B, Nagrani T,
Weinberg J, Witt K, Clark G, Cagnoni PJ.
Clin Cancer Res. 2007 Jul 1;13(13):3913-21. OSI Pharmaceuticals,
Boulder, Colorado.
[Link to Abstract]
Laparoscopic Radiofrequency
Ablation of Neuroendocrine Liver Metastases: A 10-Year Experience
Evaluating Predictors of Survival.
Mazzaglia PJ, Berber
E, Milas M, Siperstein AE.
Surgery. 2007 Jul;142(1):10-9. Rhode Island Hospital, Providence,
Rhode Island.
[Link to Abstract]
Phase II Study of Capecitabine
with Concomitant Radiotherapy for Patients with Locally Advanced
Pancreatic Cancer: Up-Regulation of Thymidine Phosphorylase.
Saif MW, Black G, Roy
S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman
D, Diasio RB.
Cancer J. 2007 Jul-Aug;13(4):247-56. Yale University School of
Medicine, New Haven, Connecticut.
[Link to Abstract]
Phase II Trial of Weekly Docetaxel/Irinotecan
Combination in Advanced Pancreatic Cancer.
Burtness B, Thomas L,
Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem
R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR.
Cancer J. 2007 Jul-Aug;13(4):257-62. Fox Chase Cancer Center,
Philadelphia, Pennsylvania.
[Link to Abstract]
JUNE
Concurrent Chemoradiotherapy
for Advanced Pancreatic Cancer : 1,000 Mg/M(2) Gemcitabine Can
Be Administered Using Limited-Field Radiotherapy.
Yamazaki H, Nishiyama
K, Koizumi M, Tanaka E, Ioka T, Uehara H, Iishi H, Nakaizumi
A, Ohigashi H, Ishikawa O.
Strahlenther Onkol. 2007 Jun;183(6):301-306. Medical Center for
Cancer and Cardiovascular Disease, Japan.
[Link to Abstract]
Dosimetric Feasibility of
Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic
Cancer Treatment.
Kozak KR, Kachnic LA,
Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez-Del Castillo
C, Ryan DP, Delaney TF, Hong TS.
I Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1557-66. [Epub
ahead of print June 4, 2007]. Massachusetts General Hospital,
Boston.
[Link to Abstract]
A New Liposomal Formulation
of Gemcitabine is Active in an Orthotopic Mouse Model of Pancreatic
Cancer Accessible to Bioluminescence Imaging.
Bornmann C, Graeser R,
Esser N, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam
U, Schaechtele C, Massing U, von Dobschuetz E.
Cancer Chemother Pharmacol. [Epub ahead of print June 7,2007].
Albert-Ludwigs-University Freiburg, Germany.
[Link to Abstract]
Successful Pancreatectomy
with En-Bloc Resection of the Celiac Artery and Portal Vein for
Pancreatic Endocrine Carcinoma.
Akatsu T, Aiura K, Shimazu
M, Ueda M, Wakabayashi G, Tanabe M, Kawachi S, Shinoda M, Kameyama
K, Kitajima M, Kitagawa Y.
IHepatogastroenterology. 2007 Jun;54(76):1269-71. Keio University
School of Medicine, Tokyo, Japan.
[Link to Abstract]
MAY
3,3',5-Triiodo-L-Thyronine
Inhibits Ductal Pancreatic Adenocarcinoma Proliferation Improving
the Cytotoxic Effect of Chemotherapy.
Michienzi S, Bucci B,
Verga Falzacappa C, Patriarca V, Stigliano A, Panacchia L, Brunetti
E, Toscano V, Misiti S.
J Endocrinol. 2007 May;193(2):209-23. University La Sapienza,
Rome, Italy.
[Link to Abstract]
Erlotinib Plus Gemcitabine
Compared with Gemcitabine Alone in Patients with Advanced Pancreatic
Cancer: A Phase III Trial of the National Cancer Institute of
Canada Clinical Trials Group.
Moore MJ, Goldstein D,
Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde
D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos
T, Ptasynski M, Parulekar W.
IJ Clin Oncol. 2007 May 20;25(15):1960-6. Princess Margaret Hospital,
Toronto, Canada.
[Link to Abstract]
Hp39p Use of the Superficial
Femoral Vein as a Conduit for Portal Vein Reconstruction During
Pancreaticoduodenectomy.
Gillespie C, Jauffret
B.
ANZ J Surg. 2007 May;77 Suppl 1:A48-9. Gisborne Hospital, New
Zealand.
[Link to Abstract]
Phase II Trial of Infusional
Fluorouracil, Leucovorin, Mitomycin, and Dipyridamole in Locally
Advanced Unresectable Pancreatic Adenocarcinoma: SWOG S9700.
Isacoff WH, Bendetti
JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA.
J Clin Oncol. 2007 May 1;25(13):1665-9. University of California,
Los Angeles Medical Center.
[Link to Abstract]
APRIL
Erbb3 Expression and Dimerization
with EGFR Influence Pancreatic Cancer Cell Sensitivity to Erlotinib.
Frolov A, Schuller K,
Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ,
Buchsbaum DJ, Arnoletti JP.
Cancer Biol Ther. 2007 Apr 13;6(4) [Epub]. University of Alabama
at Birmingham, Alabama.
[Link to Abstract]
The Gemcitabine, Docetaxel,
and Capecitabine (GTX) Regimen for Metastatic Pancreatic Cancer:
A Retrospective Analysis.
Fine RL, Fogelman DR,
Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade
R, Chabot J.
Cancer Chemother Pharmacol. 2007 Apr 18; [Epub]. New York Presbyterian
Medical Center, Columbia University College of Physicians and
Surgeons, New York.
[Link to Abstract]
A Phase I Pilot Study of Autologous
Heat Shock Protein Vaccine HSPPC-96 in Patients with Resected
Pancreatic Adenocarcinoma.
Maki RG, Livingston PO,
Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK,
Brennan MF.
Dig Dis Sci. 2007 Apr 10; [Epub]. Memorial Sloan- Kettering Cancer
Center, New York.
[Link to Abstract]
A Randomized Phase 2 Trial
of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer:
Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin.
Palmer DH, Stocken DD,
Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall
SR.
Ann Surg Oncol. 2007 Jul;14(7):2088-96. 2007 Apr 24; [Epub].
Cancer Research UK Institute for Cancer Studies and Clinical
Trials Unit, University of Birmingham, UK.
[Link to Abstract]
MARCH
Full-Dose Gemcitabine and
Concurrent Radiotherapy for Unresectable Pancreatic Cancer.
Murphy JD, Adusumilli
S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E.
Int J Radiat Oncol Biol Phys. 2007 Mar 20, Epub. University of
Michigan, Ann Arbor, MI, USA.
[Link to Abstract]
A Phase II Study of Fixed-Dose
Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative
Chemoradiation for Locally Advanced Pancreatic Cancer.
Ko AH, Quivey JM, Venook
AP, Bergsland EK, Dito E, Schillinger B, Tempero MA.
Int J Radiat Oncol Biol Phys. 2007 Mar 13, Epub. University of
California at San Francisco, CA, USA.
[Link to Abstract]
A Phase II Trial of Gemcitabine
Plus Capecitabine for Patients with Advanced Pancreatic Adenocarcinoma.
Park BB, Park JO, Lee
HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim DH,
Park YS, Lim HY, Kang WK, Park K.
Cancer Chemother Pharmacol. 2007 Mar 30, Epub. Sungkyunkwan University
School of Medicine, Seoul, South Korea.
[Link to Abstract]
Pooled Efficacy Analysis from
a Phase I-II Study of Biweekly Irinotecan in Combination with
Gemcitabine, 5-Fluorouracil, Leucovorin and Cisplatin in Patients
with Metastatic Pancreatic Cancer.
Goel A, Grossbard ML,
Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch
P.
Anticancer Drugs. 2007 Mar;18(3):263-71. St Luke's-Roosevelt
Hospital Center, New York, NY, USA.
[Link to Abstract]
FEBRUARY
Aggressive Surgery Improves
Long-Term Survival in Neuroendocrine Pancreatic Tumors: An Institutional
Experience.
Schurr PG, Strate T,
Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF,
Izbicki JR.
Ann Surg. 2007 Feb;245(2):273-81. University Medical Center of
Hamburg-Eppendorf, University of Hamburg, Germany.
[Link to Abstract]
FOLFOX-6 Combination as the
First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic
Cancer.
Ghosn M, Farhat F, Kattan
J, Younes F, Moukadem W, Nasr F, Chahine G.
Am J Clin Oncol. 2007 Feb;30(1):15-20. Hotel-Dieu de France University
Hospital, Beirut, Lebanon.
[Link to Abstract]
In Vitro and In Vivo Molecular
Evidence of Genistein Action in Augmenting the Efficacy of Cisplatin
in Pancreatic Cancer.
Banerjee S, Zhang Y,
Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH.
Int J Cancer. 2007 Feb 15;120(4):906-17. Barbara Ann Karmanos
Cancer Institute, Wayne State University School of Medicine,
Detroit, Michigan.
[Link to Abstract]
Low-Dose Radiotherapy as a
Chemopotentiator of Gemcitabine in Tumors of the Pancreas or
Small Bowel: A Phase I Study Exploring a New Treatment Paradigm.
Regine WF, Hanna N, Garofalo
MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M.
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):172-7. [Epub 2007
Feb 2]. University of Maryland, Baltimore, Maryland.
[Link to Abstract]
JANUARY
Clinical and In Vitro Studies
of Imatinib in Advanced Carcinoid Tumors.
Yao JC, Zhang JX, Rashid
A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL,
Ajani JA.
Clin Cancer Res. 2007 Jan 1;13(1):234-40. The University of Texas
/ M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Impact of Interferon-Alpha
in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma
(Capri): First Data from the Immunomonitoring.
Schmidt J, Jager D, Hoffmann
K, Buchler MW, Marten A.
J Immunother. 2007 Jan;30(1):108-15. University of Heidelberg,
Germany.
[Link to Abstract]
Phase I Study of Oral S-1
and Concurrent Radiotherapy in Patients with Unresectable Locally
Advanced Pancreatic Cancer.
Sudo K, Yamaguchi T,
Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno
T, Ito H, Saisho H.
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):219-24. Graduate
School of Medicine, Chiba University, Inohana, Chiba, Japan.
[Link to Abstract]
Second-Line Chemotherapy with
Pemetrexed After Gemcitabine Failure in Patients with Advanced
Pancreatic Cancer: A Multicenter Phase II Trial.
Boeck S, Weigang-Kohler
K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stotzer O, Zeuzem
S, Lordick F, Kohne CH, Kroning H, Steinmetz T, Depenbrock H,
Heinemann V.
Ann Oncol. 2007 Apr;18(4):745-51. Epub 2007 Jan 17. University
Hospital Grosshadern, Ludwigs-Maximilians University, Munich,
Germany.
[Link to Abstract]
2006
DECEMBER
An Aggressive Surgical Approach
Leads to Long-Term Survival in Patients with Pancreatic Endocrine
Tumors.
Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy
A, Rothmund M.
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3. Philipps-University
Marburg, Germany.
[Link to Abstract]
Erlotinib Plus Gemcitabine
in Patients with Unresectable Pancreatic Cancer and Other Solid
Tumors: Phase IB Trial.
Dragovich T, Huberman
M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage
G, Wolf J, Patnaik A.
Cancer Chemother Pharmacol. 2006 Dec 6, Epub. University of Arizona,
Tucson, Arizona.
[Link to Abstract]
Low Molecular Weight Heparin
(LMWH) Increases the Efficacy of Cisplatinum Plus Gemcitabine
Combination in Advanced Pancreatic Cancer.
Icli F, Akbulut H, Utkan
G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay
F, Buyukcelik A.
J Surg Oncol. 2006 Dec 27, Epub. Ankara University School of
Medicine, Turkey.
[Link to Abstract]
Phase II Study of Cisplatin
Combined With Weekly Gemcitabine in the Treatment of Patients
with Metastatic Pancreatic Carcinoma.
Bang S, Jeon TJ, Kim MH, Park JY, Park SW, Chung JB, Song SY.
Pancreatology. 2006 Dec 6;6(6):635-641, Epub. Yonsei University
College of Medicine, Seoul, Korea.
[Link to Abstract]
FOLFIRI.3, A New Regimen Combining
5-Fluorouracil, Folinic Acid and Irinotecan, for Advanced Pancreatic
Cancer: Results of an Association Des Gastro-Enterologues Oncologues
(Gastroenterologist Oncologist Association) Multicenter Phase
II Study.
Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru
P, Fallik D, Spano J, Landi B, Lledo G, Desrame J.
Ann Oncol. 2006 Dec 8, Epub. Groupe Hospitalier Pitie Salpetriere,
Paris, France.
[Link to Abstract]
NOVEMBER
Intra-Arterial Infusion of
5-Fluorouracil, Leucovorin, Epirubicin and Carboplatin (FLEC
Regimen) in Unresectable Pancreatic Cancer: Results of a Ten-Year
Experience.
Mambrini A, Sanguinetti F, Pacetti P, Caudana R, Iacono C, Guglielmi
A, Guadagni S, Del Freo A, Fiorentini G, Cantore M.
In Vivo. 2006 Nov-Dec;20(6A):751-5. Massa-Carrara City Hospital,
Italy.
[Link to Abstract]
Potentiation of the Effect
of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt
and Nuclear Factor-Kappab.
El-Rayes BF, Ali S, Ali
IF, Philip PA, Abbruzzese J, Sarkar FH.
Cancer Res. 2006 Nov 1;66(21):10553-9. Karmanos Cancer Institute,
Wayne State University, Detroit, Michigan.
[Link to Abstract]
Radiofrequency Ablation Combined
with Palliative Surgery May Prolong Survival of Patients with
Advanced Cancer of The Pancreas.
Spiliotis JD, Datsis
AC, Michalopoulos NV, Kekelos SP, Vaxevanidou A, Rogdakis AG,
Christopoulou AN.
Langenbecks Arch Surg. 2007 Jan;392(1):55-60. Epub 2006 Nov 7.
Hatzikostas General Hospital, Messologi, Greece.
[Link to Abstract]
Rapamycin Synergizes with
the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell
Lung, Pancreatic, Colon, and Breast Tumors.
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD,
Iwata KK, Gibson NW, Griffin G.
Mol Cancer Ther. 2006 Nov;5(11):2676-84. OSI Pharmaceuticals,
Farmingdale, New York.
[Link to Abstract]
OCTOBER
Clinical Results on Intra-Arterial
Adjuvant Chemotherapy for Prevention of Liver Metastasis Following
Curative Resection of Pancreatic Cancer.
Hayashibe A, Kameyama
M, Shinbo M, Makimoto S.
Ann Surg Oncol. 2007 Jan;14(1):190-4. Epub 2006 Oct 26. Bell
Land General Hospital, Sakai City, Osaka, Japan.
[Link to Abstract]
Pancreatic Resection for M1
Pancreatic Ductal Adenocarcinoma.
Shrikhande SV, Kleeff
J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H,
Buchler MW.
Ann Surg Oncol. 2007 Jan;14(1):118-27.Epub 2006 Oct 25. Tata
Memorial Hospital, Mumbai, India.
[Link to Abstract]
RP101 Improves the Efficacy
of Chemotherapy in Pancreas Carcinoma Cell Lines and Pancreatic
Cancer Patients.
Fahrig R, Quietzsch D,
Heinrich JC, Heinemann V, Boeck S, Schmid RM, Praha C, Liebert
A, Sonntag D, Krupitza G, Hanel M.
Anticancer Drugs. 2006 Oct;17(9):1045-56. RESprotect, Dresden
Germany.
[Link to Abstract]
Telomerase Peptide Vaccination
of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating
Phase I/II Study.
Bernhardt SL, Gjertsen
MK, Trachsel S, Moller M, Eriksen JA, Meo M, Buanes T, Gaudernack
G.
Br J Cancer. 2006 Dec 4;95(11):1474-82. Epub 2006 Oct 24. Ulleval
University Hospital, Oslo, Norway.
[Link to Abstract]
SEPTEMBER
Effects of Low-Dose Warfarin
and Regional Chemotherapy on Survival in Patients with Pancreatic
Carcinoma.
Nakchbandi W, Muller
H, Singer MV, Lohr M, Nakchbandi IA.
Scand J Gastroenterol. 2006 Sep;41(9):1095-104. Carl von Hess
Hospital, Hammelburg, Germany.
[Link to Abstract]
Pancreatic Resections after
Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma:
Analysis of Perioperative Outcome and Survival.
Massucco P, Capussotti
L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele
P, Aglietta M.
Ann Surg Oncol. 2006 Sep;13(9):1201-8. Institute for Research
and Cure of Cancer, Candiolo, Italy.
[Link to Abstract]
Postoperative Morbidity and
Long-Term Survival after Pancreaticoduodenectomy with Superior
Mesenterico-Portal Vein Resection.
Riediger H, Makowiec
F, Fischer E, Adam U, Hopt UT.
J Gastrointest Surg. 2006 Sep-Oct;10(8):1106-15. University of
Freiburg, Germany.
[Link to Abstract]
Staging of Pancreatic Cancer
with Multidetector CT in the Setting of Preoperative Chemoradiation
Therapy.
Tamm EP, Loyer EM, Faria
S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej
C.
Abdom Imaging. 2006 Sep 12; [Epub]. University of Texas / M.D.
Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
AUGUST
Antitumor Effect of Trastuzumab
for Pancreatic Cancer with High HER-2 Expression and Enhancement
of Effect by Combined Therapy with Gemcitabine.
Kimura K, Sawada T, Komatsu
M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira
M, Hirakawa K.
Clin Cancer Res. 2006 Aug 15;12(16):4925-32. Osaka City University
Graduate School of Medicine, Japan.
[Link to Abstract]
Are Capecitabine and Oxaliplatin
(XELOX) Suitable Treatments for Progressing Low-Grade and High-Grade
Neuroendocrine Tumours?
Bajetta E, Catena L,
Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A,
Platania M, Verzoni E, Formisano B, Bajetta R.
Cancer Chemother Pharmacol. 2006 Aug 26; [Epub]. Istituto Nazionale
per lo Studio e la Cura dei Tumori, Milan, Italy.
[Link to Abstract]
Randomized Phase III Trial
of Gemcitabine Plus Cisplatin Compared with Gemcitabine Alone
in Advanced Pancreatic Cancer.
Heinemann V, Quietzsch
D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H,
Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein
D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A,
Schalhorn A, Wilkowski R.
J Clin Oncol. 2006 Aug 20;24(24):3946-52. Klinikum Grosshadern,
Munich, Germany.
[Link to Abstract]
Resection of Pancreatic Neuroendocrine
Tumors: Results of 70 Cases.
Kazanjian KK, Reber HA,
Hines OJ.
Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70. University
of California, Los Angeles.
[Link to Abstract]
JULY
Chemoradiotherapy with Gemcitabine
and Continuous 5-FU in Patients with Primary Inoperable Pancreatic
Cancer.
Wilkowski R, Thoma M,
Bruns C, Wagner A, Heinemann V.
JOP. 2006 Jul 10;7(4):349-60. LMU University Hospital Grosshadern,
Munich, Germany.
[Link to Abstract]
Interferon-Alpha + Cisplatin
+ 5-FU Therapy for Gemcitabine-Refractory Unresectable and Recurrent
Pancreatic Cancer.
Ueda M, Endo I, Fujii
Y, Miura Y, Kubota T, Tanaka K, Ichikawa Y, Togo S, Shimada H.
Gan To Kagaku Ryoho. 2006 Jul;33(7):937-40. Yokohama City University
Graduate School of Medicine, Japan.
[Link to Abstract]
Phase I/II Trial of Hyperfractionated
Accelerated Chemoradiotherapy for Unresectable Advanced Pancreatic
Cancer.
Tsujie M, Nakamori S,
Tanaka E, Nagano H, Umeshita K, Dono K, Sakon M, Inoue T, Inoue
T, Monden M.
Jpn J Clin Oncol. 2006 Aug;36(8):504-10. Epub 2006 Jul 19. Osaka
National Hospital, Japan.
[Link to Abstract]
A Phase II Study of Weekly
Irinotecan as First-Line Therapy for Patients with Metastatic
Pancreatic Cancer.
Ueno H, Okusaka T, Funakoshi
A, Ishii H, Yamao K, Ishikawa O, Ohkawa S, Saitoh S.
Cancer Chemother Pharmacol. 2006 Jul 20;[Epub]. National Cancer
Center Hospital, Tokyo, Japan.
[Link to Abstract]
JUNE
Combination Chemotherapy with
Gemcitabine and S-1 for Advanced Pancreatic Cancer.
Nakamura K, Yamaguchi
T, Sudo K, Ishihara T, Saisho H.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:219-23. Shimizu Kousei
Hospital, Shizuoka, Japan.
[Link to Abstract]
Dose-Intense PEFG (Cisplatin,
Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic
Adenocarcinoma.
Reni M, Cereda S, Bonetto
E, Vigano MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher
C, Di Carlo V.
Cancer Chemother Pharmacol. 2006 Jun 29; [Epub]. San Raffaele
Scientific Institute, Milan, Italy.
[Link to Abstract]
Phase I and Pharmacokinetic
Study of S-1 Administered for 14 Days in a 21-Day Cycle in Patients
with Advanced Upper Gastrointestinal Cancer.
Zhu AX, Clark JW, Ryan
DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E,
Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.
Cancer Chemother Pharmacol. 2006 Jun 20; [Epub]. Massachusetts
General Hospital, Boston.
[Link to Abstract]
S-1 Monotherapy for Pancreatic
Cancer.
Okusaka T, Ueno H, Ikeda
M, Morizane C.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:207-12. National Cancer
Center Hospital, Tokyo, Japan.
[Link to Abstract]
MAY
Liposomal Cisplatin Combined
with Gemcitabine in Pretreated Advanced Pancreatic Cancer Patients:
A Phase I-II Study.
Stathopoulos GP, Boulikas
T, Vougiouka M, Rigatos SK, Stathopoulos JG.
Oncol Rep. 2006 May;15(5):1201-4. Errikos Dunant Hospital and
Medical School of Athens, Greece.
[Link to Abstract]
Phase I Study of The Humanised
Anti-EGFR Monoclonal Antibody Matuzumab (EMD 72000) Combined
with Gemcitabine in Advanced Pancreatic Cancer.
Graeven U, Kremer B,
Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel
W. Br J Cancer. 2006 May 8;94(9):1293-9. Ruhr University Bochum,
and University Hospital of Schleswig-Holstein, Kiel, Germany.
[Link to Abstract]
A Phase II Trial of Epothilone
B Analogue BMS-247550 (NSC #710428) Ixabepilone, in Patients
with Advanced Pancreas Cancer: A Southwest Oncology Group Study.
Whitehead RP, McCoy S,
Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin
JW, Dakhil SR, Abbruzzese JL.
Invest New Drugs. 2006 May 11;[Epub]. University of Texas Medical
Branch, Galveston, Texas.
[Link to Abstract]
Unfavourable Prognosis Associated
with K-Ras Gene Mutation in Pancreatic Cancer Surgical Margins
Kim J, Reber HA, Dry
SM, Elashoff D, Chen SL, Umetani N, Kitago M, Hines OJ, Kazanjian
KK, Hiramatsu SH, Bilchik AJ, Yong S, Shoup M, Hoon DS.
Gut. 2006 May 8;[Epub]. John Wayne Cancer Institute, Santa Monica,
California.
[Link to Abstract]
APRIL
Adjuvant Intra-Arterial 5-Fluoruracil,
Leucovorin, Epirubicin and Carboplatin With or Without Systemic
Gemcitabine After Curative Resection for Pancreatic Adenocarcinoma.
Cantore M, Serio G, Pederzoli
P, Mambrini A, Iacono C, Pulica C, Capelli P, Lombardi M, Torri
T, Pacetti P, Pagani M, Fiorentini G.
Cancer Chemother Pharmacol. 2006 Apr 22; Epub. General City Hospital,
Massa Carrara, Italy.
[Link to Abstract]
The Argument for Pre-operative
Chemoradiation for Localized, Radiographically Resectable Pancreatic
Cancer.
Crane CH, Varadhachary
G, Wolff RA, Pisters PW, Evans DB.
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):365-82. University
of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Maintenance Chemotherapy After
Chemoradiation Improves Survival of Patients with Locally Advanced
Pancreatic Carcinoma: A Retrospective Analysis of Prospectively
Recruited Patients.
Brunner TB, Tinkl D,
Grabenbauer GG, Meyer T, Brueckl WM, Sauer R.
Strahlenther Onkol. 2006 Apr;182(4):210-5. Friedrich Alexander
University of Erlangen-Nuremberg, Germany.
[Link to Abstract]
Venous Resection in Pancreatic
Cancer Surgery.
Tseng JF, Tamm EP, Lee
JE, Pisters PW, Evans DB.
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64. University
of Massachusetts Medical School, Worcester, Massachusetts.
[Link to Abstract]
MARCH
The Long-Term Survival of
a Patient with Pancreatic Cancer with Metastases to the Liver
after Treatment with the Intravenous alpha-lipoic acid/low-dose
naltrexone Protocol.
Berkson BM, Rubin DM,
Berkson AJ.
Integr Cancer Ther. 2006 Mar;5(1):83-9. Integrative Medical Center
of New Mexico and New Mexico State University, Las Cruces, New
Mexico.
[Link to Abstract]
A Phase I Study of Oral Uracil-Tegafur
Prior to Weekly Intravenous Gemcitabine in Patients with Advanced
Pancreatic Cancer.
Tanno S, Nakano Y, Osanai
M, Koizumi K, Izawa T, Habiro A, Mizukami Y, Yanagawa N, Fujii
T, Okumura T, Kohgo Y.
Chemotherapy. 2006;52(2):98-102. Epub 2006 Mar 27. Asahikawa
Medical College, Asahikawa, Japan.
[Link to Abstract]
Phase I Trial Evaluating the
Safety of Bevacizumab with Concurrent Radiotherapy and Capecitabine
in Locally Advanced Pancreatic Cancer.
Crane CH, Ellis LM, Abbruzzese
JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters
PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA.
J Clin Oncol. 2006 Mar 1;24(7):1145-51. University of Texas /
M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Raltitrexed-Eloxatin Salvage
Chemotherapy in Gemcitabine-Resistant Metastatic Pancreatic Cancer.
Reni M, Pasetto L, Aprile
G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza
C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo
V, Brandes AA.
Br J Cancer. 2006 Mar 27;94(6):785-91. San Raffaele Scientific
Institute., Milan, Italy.
[Link to Abstract]
FEBRUARY
Evaluation of the Efficacy
of Combined Continuous Arterial Infusion and Systemic Chemotherapy
for the Treatment of Advanced Pancreatic Carcinoma.
Ikeda O, Kusunoki S,
Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y.
Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):362-70. Kumamoto
University Graduate School of Medical and Pharmaceutical Sciences,
Japan.
[Link to Abstract]
Immunomodulatory Impact of
Interferon-Alpha in Combination with Chemoradiation of Pancreatic
Adenocarcinoma (Capri).
Schmidt J, Patrut EM,
Ma J, Jager D, Knaebel HP, Buchler MW, Marten A.
Cancer Immunol Immunother. 2006 Epub Feb 17, 2006. University
of Heidelberg, Germany.
[Link to Abstract]
Multicenter Phase-I/II Study
Using a Combination of Gemcitabine and Docetaxel in Metastasized
and Unresectable, Locally Advanced Pancreatic Carcinoma.
Ridwelski K, Fahlke J,
Kuhn R, Hribaschek A, Kettner E, Greiner C, Florschuetz A, Manger
T, Wilhelm G, Klein H, Hahnfeld S, Lippert H, Meyer F.
Eur J Surg Oncol. 2006 Apr;32(3):297-302. Epub 2006 Jan 18. Otto
von Guericke University, Magdeburg, Germany.
[Link to Abstract]
Phase II Study 0f Temozolomide
and Thalidomide in Patients with Metastatic Neuroendocrine Tumors.
Kulke MH, Stuart K, Enzinger
PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A,
Fuchs CS.
J Clin Oncol. 2006 Jan 20;24(3):401-6. Dana-Farber Cancer Institute,
Boston, Massachusetts.
[Link to Abstract]
JANUARY
Comparison of Standard-Dose
and Low-Dose Gemcitabine Regimens in Pancreatic Adenocarcinoma
Patients: A Prospective Randomized Trial.
Sakamoto H, Kitano M,
Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M.
J Gastroenterol. 2006 Jan;41(1):70-6. Kinki University School
of Medicine, Osaka-Sayama, Japan.
[Link to Abstract]
Gemcitabine and Oxaliplatin
(GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma:
A Phase II Study.
Demols A, Peeters M,
Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem
JL.
Br J Cancer. 2006 Feb 27;94(4):481-5 (Epub 2006 Jan24). Erasme
University Hospital, Brussels, Belgium.
[Link to Abstract]
A Multi-Institutional Phase
II Trial of Preoperative Full-Dose Gemcitabine and Concurrent
Radiation for Patients with Potentially Resectable Pancreatic
Carcinoma.
Talamonti MS, Small W
Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM,
Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ.
Ann Surg Oncol. 2006 Feb;13(2):150-8 (Epub 2006 Jan 19). Feinberg
School of Medicine, Northwestern University, Chicago.
[Link to Abstract]
Phase II Study of Fixed Dose
Rate Gemcitabine with Cisplatin for Metastatic Adenocarcinoma
of The Pancreas.
Ko AH, Dito E, Schillinger
B, Venook AP, Bergsland EK, Tempero MA.
J Clin Oncol. 2006 Jan 20;24(3):379-85. University of California
at San Francisco Comprehensive Cancer Center, San Francisco.
[Link to Abstract]
2005
DECEMBER
Brief Communication: A New
Combination in the Treatment of Advanced Pancreatic Cancer.
Moore MJ.
Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6. Princess Margaret Hospital,
Toronto, Canada.
[Link to Abstract]
Chemoradiotherapy in Patients
with Pancreatic Carcinoma: Phase-I Study with a Fixed Radiation
Dose and Escalating Doses of Weekly Gemcitabine.
Oya N, Shibuya K, Sakamoto
T, Mizowaki T, Doi R, Fujimoto K, Imamura M, Nagata Y, Hiraoka
M.
Pancreatology. 2005 Dec 1;6(1-2):109-116. Graduate School of
Medicine, Kyoto University, Japan.
[Link to Abstract]
Docetaxel Plus Gemcitabine
or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma:
Randomized Phase II Study 40984 of The European Organisation
for Research and Treatment of Cancer Gastrointestinal Group.
Lutz MP, Cutsem EV, Wagener
T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH,
Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne
PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger
B, Ducreux MP.
J Clin Oncol. 2005 Dec 20;23(36):9250-6. University of Ulm, Germany
[Link to Abstract]
Erlotinib and Chemoradiation
Followed by Maintenance Erlotinib for Locally Advanced Pancreatic
Cancer: A Phase I Study.
Iannitti D, Dipetrillo
T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, Miner T, Martel
D, Cioffi W, Remis M, Kennedy T, Safran H.
Am J Clin Oncol. 2005 Dec;28(6):570-5. Brown University Oncology
Group, Providence, Rhode Island.
[Link to Abstract]
NOVEMBER
Complete Remission of Liver
Metastasis of Pancreatic Cancer Under Vaccination with a HLA-A2
Restricted Peptide Derived from the Universal Tumor Antigen Survivin.
Wobser M, Keikavoussi
P, Kunzmann V, Weininger M, Andersen MH, Becker JC.
Cancer Immunol Immunother. 2005 Nov 29;1-5. University of Wuerzburg,
Germany.
[Link to Abstract]
Docetaxel/Gemcitabine Followed
by Gemcitabine and External Beam Radiotherapy in Patients with
Pancreatic Adenocarcinoma.
Pipas JM, Barth RJ Jr,
Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple
GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N,
Meyer LP, Marshall JF, Cole BF, Colacchio TA.
Ann Surg Oncol. 2005 Dec;12(12):995-1004. Epub 2005 Nov 1. Dartmouth-Hitchcock
Medical Center/Norris Cotton Cancer Center, Lebanon, New Hampshire.
[Link to Abstract]
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients with
Advanced Pancreatic Cancer.
Kindler HL, Friberg G,
Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T,
Dachman A, Stadler WM, Vokes EE.
J Clin Oncol. 2005 Nov 1;23(31):8033-40. University of Chicago
Medical Center, Illinois.
[Link to Abstract]
Phase III Randomised Comparison
of Gemcitabine (GEM) Versus Gemcitabine Plus Capecitabine (GEM-CAP)
in Patients with Advanced Pancreatic Cancer.
Chua YJ, Cunningham D,
et al.
European Cancer Conference (ECCO 13), presentation/abstract PS11,
Paris, France, 2005 November 2. Royal Marsden Hospital, London,
England.
[Link to Abstract]
OCTOBER
Borderline Resectable Pancreatic
Cancer.
Varadhachary GR, Tamm
EP, Crane C, Evans DB, Wolff RA
Curr Treat Options Gastroenterol. 2005 Oct;8(5):377-84. M.D.
Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Combination Therapy for Advanced
Pancreatic Cancer Using Herceptin Plus Chemotherapy.
Buchler P, Reber HA,
Eibl G, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ.
Int J Oncol. 2005 Oct;27(4):1125-30. University of Heidelberg,
Germany.
[Link to Abstract]
Combined Systemic and Intraarterial
Chemotherapy with Gemcitabine and Concomitant External-Beam Radiotherapy
in Patients with Liver Metastasis from Pancreatic Cancer - A
Report of Two Cases.
Matsugu Y, Tanaka T,
Kagawa N, Nakahara H, Ishimoto T, Fukuda Y.
Gan To Kagaku Ryoho. 2005 Oct;32(10):1489-92. Hiroshima Prefectural
Hospital, Japan.
[Link to Abstract]
Phase II Study to Assess the
Efficacy of Conventionally Fractionated Radiotherapy Followed
By a Stereotactic Radiosurgery Boost in Patients with Locally
Advanced Pancreatic Cancer.
Koong AC, Christofferson
E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco
R, Norton J, Yang GP.
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3. Stanford
University School of Medicine, Stanford, California.
[Link to Abstract]
SEPTEMBER
Bevacizumab as Treatment for
Chemotherapy-Resistant Pancreatic Cancer.
Bruckner HW, Hrehorovich
VR, Sawhney HS.
Anticancer Res. 2005 Sep-Oct;25(5):3637-9. Lutheran Medical Center,
Brooklyn, New York.
[Link to Abstract]
Fixed Dose-Rate Gemcitabine
Infusion as First-Line Treatment for Advanced-Stage Carcinoma
of The Pancreas and Biliary Tree.
Gelibter A, Malaguti
P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre
GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella
M.
Cancer. 2005 Sep 15;104(6):1237-45. Regina Elena National Cancer
Institute, Rome, Italy.
[Link to Abstract]
Gemcitabine Plus Celecoxib
(GECO) in Advanced Pancreatic Cancer: A Phase II Trial.
Ferrari V, Valcamonico
F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, Rangoni G,
Grisanti S, Tiberio GA, Nodari F, Strina C, Marini G.
Cancer Chemother Pharmacol. 2005 Sep 3;:1-6. U.O. Oncologia Medica,
Beretta Foundation, Brescia, Italy.
[Link to Abstract]
Surgical Resection After Radiochemotherapy
in Patients with Unresectable Adenocarcinoma of the Pancreas.
Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Bellannee
G, Brunet R, Collet D, Masson B.
J Am Coll Surg. 2005 Sep;201(3):359-65. Groupe Hospitalier Sud,
CHU Bordeaux, Pessac, France.
[Link to Abstract]
AUGUST
Adjuvant Gemcitabine and Concurrent
Continuous Radiation (45 Gy) for Resected Pancreatic Head Carcinoma:
A Multicenter Belgian Phase II Study.
Demols A, Peeters M,
Polus M, Honore P, Boterberg T, Gay F, Closon MT, Van Houtte
P, Closset J, Van Laethem JL.
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1351-6. Erasme
University Hospital, Brussels, Belgium.
[Link to Abstract]
Phase II Study on Low Dose
Gemcitabine Plus Oral Chemotherapy with Uracil-Tegafur and Cyclophosphamide
in Combination with Radiotherapy Against Recurrent and Advanced
Pancreatic Cancer.
Nio Y, Hashimoto K, Yano
S, Itakura M, Koike M, Yamaguchi K, Endo S, Tsuji M, Higami T,
Maruyama R.
Oncol Rep. 2005 Aug;14(2):401-8. Shimane University School of
Medicine, Japan.
[Link to Abstract]
Second-Line Treatment with
Oxaliplatin, Leucovorin and 5-Fluorouracil in Gemcitabine-Pretreated
Advanced Pancreatic Cancer: A Phase II Study.
Tsavaris N, Kosmas C,
Skopelitis H, Gouveris P, Kopteridis P, Loukeris D, Sigala F,
Zorbala-Sypsa A, Felekouras E, Papalambros E.
Invest New Drugs. 2005 Aug;23(4):369-75. Metaxa Memorial Cancer
Hospital, Piraeus, Greece.
[Link to Abstract]
Toxicities and Effects of
Involved-Field Irradiation with Concurrent Cisplatin for Unresectable
Carcinoma of The Pancreas.
Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi
T, Saisho H, Kawata T, Ito H.
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1357-62. Chiba
University Graduate School of Medicine, Japan.
[Link to Abstract]
JULY
An Early Phase II Study of
S-1 in Patients with Metastatic Pancreatic Cancer.
Ueno H, Okusaka T, Ikeda
M, Takezako Y, Morizane C.
Oncology. 2005;68(2-3):171-8. 2005 Jul 4. National Cancer Center
Hospital, Tokyo, Japan.
[Link to Abstract]
Feasibility of US-Guided High-Intensity
Focused Ultrasound Treatment in Patients with Advanced Pancreatic
Cancer: Initial Experience.
Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, Li KQ, Jin CB,
Xie FL, Su HB.
Radiology. 2005 Sep;236(3):1034-40. 2005 Jul 29. Chongqing University
of Medical Sciences, Chongqing, China
[Link to Abstract]
Phase II Trial of Primary
Radiation Therapy and Concurrent Chemotherapy for Patients with
Locally Advanced Pancreatic Cancer.
Magnino A, Gatti M, Massucco
P, Sperti E, Faggiuolo R, Regge D, Capussotti L, Gabriele P,
Aglietta M.
Oncology. 2005;68(4-6):493-9. 2005 Jul 13. Institute for Research
and Cure of Cancer, Candiolo, Italy.
[Link to Abstract]
Serum CA19-9 Response as a
Surrogate for Clinical Outcome in Patients Receiving Fixed-Dose
Rate Gemcitabine for Advanced Pancreatic Cancer.
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero
MA.
Br J Cancer. 2005 Jul 25;93(2):195-9. University of California
at San Francisco Comprehensive Cancer Center.
[Link to Abstract]
JUNE
Gemcitabine Versus Cisplatin,
Epirubicin, Fluorouracil, and Gemcitabine in Advanced Pancreatic
Cancer: A Randomised Controlled Multicentre Phase III Trial.
Reni M, Cordio S, Milandri
C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli
L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L,
Staudacher C, Villa E, Di Carlo V.
Lancet Oncol. 2005 Jun;6(6):369-76. S Raffaele H Scientific Institute,
Milan, Italy.
[Link to Abstract]
A Novel Anti-Pancreatic Cancer
Agent, LY293111.
Ding XZ, Talamonti MS, Bell RH Jr, Adrian TE.
Anticancer Drugs. 2005 Jun;16(5):467-73. Feinberg School of Medicine,
Northwestern University, Chicago, Illinois.
[Link to Abstract]
Phase I Trial of Oral S-1
Combined with Gemcitabine in Metastatic Pancreatic Cancer.
Nakamura K, Yamaguchi
T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho
H.
Br J Cancer. 2005 Jun 20;92(12):2134-9. Graduate School of Medicine,
Chiba University, Inohana, Chiba, Japan.
[Link to Abstract]
A Phase II Study of Alternating
Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy
for Inoperable Pancreatic or Biliary Tract Carcinoma.
Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM,
Tan B, Thorstad WL, Myerson R.
Am J Clin Oncol. 2005 Jun;28(3):234-41. Washington University
School of Medicine, St. Louis, Missouri.
[Link to Abstract]
MAY
Clinical Experience with Chronomodulated
Infusional 5-Fluorouracil Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keene KS, Rich TA, Penberthy
DR, Shepard RC, Adams R, Jones RS.
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):97-103. University
of Virginia Health Science Center, Charlottesville, Virginia.
[Link to Abstract]
Epidermal Growth Factor Receptor
and Activated Epidermal Growth Factor Receptor Expression in
Gastrointestinal Carcinoids and Pancreatic Endocrine Carcinomas.
Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman
C, Ames MM, Lloyd RV.
Mod Pathol. 2005 May 6 [Epub]. Mayo Clinic College of Medicine,
Rochester, Minnesota.
[Link to Abstract]
Neuroendocrine Hepatic Metastases:
Does Aggressive Management Improve Survival?
Touzios JG, Kiely JM,
Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA.
Ann Surg. 2005 May;241(5):776-83; discussion 783-5. Medical College
of Wisconsin, Milwaukee, Wisconsin.
[Link to Abstract]
A Phase II Study of Combination
Chemotherapy with Gemcitabine, 5-Fluorouracil, and Cisplatin
for Advanced Pancreatic Cancer.
Choi SB, Lee HY, Yuh YJ, Kim SR.
Korean J Gastroenterol. 2005 May;45(5):348-53. Inje University
Collage of Medicine, Sanggye Paik Hospital, Seoul, Korea.
[Link to Abstract]
APRIL
5-Fluorouracil Intra-Arterial
Infusion Combined with Systemic Gemcitabine for Unresectable
Pancreatic Cancer.
Takamori H, Kanemitsu
K, Tsuji T, Tanaka H, Chikamoto A, Nakahara O, Hiraoka T, Ikeda
O, Kudo K, Imuta M, Yamashita Y.
Pancreas. 2005 Apr;30(3):223-6. Graduate School of Medical Sciences,
Kumamoto University, Japan.
[Link to Abstract]
Meta-Analysis of Randomised
Adjuvant Therapy Trials for Pancreatic Cancer.
Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl
JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP; Pancreatic
Cancer Meta-analysis Group.
Br J Cancer. 2005 Apr 25;92(8):1372-81. University of Birmingham,
UK.
[Link to Abstract]
Parthenolide and Sulindac
Cooperate to Mediate Growth Suppression and Inhibit the Nuclear
Factor-Kappa B Pathway in Pancreatic Carcinoma Cells.
Yip-Schneider MT, Nakshatri
H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM.
Mol Cancer Ther. 2005 Apr;4(4):587-94. Indiana University School
of Medicine, Indianapolis, Indiana.
[Link to Abstract]
Thalidomide in the Treatment
of Cancer Cachexia: A Randomised Placebo Controlled Trial.
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM.
Gut. 2005 Apr;54(4):540-5. Southampton General Hospital, England.
[Link to Abstract]
MARCH
Increased Preoperative Platelet
Count is Associated with Decreased Survival After Resection for
Adenocarcinoma of The Pancreas.
Brown KM, Domin C, Aranha
GV, Yong S, Shoup M.
Am J Surg. 2005 Mar;189(3):278-82. Loyola University Medical
Center, Maywood, Illinois
[Link to Abstract]
Intra-Arterial Bolus Octreotide
Administration During Whipple Procedure in Patients with Fragile
Pancreas: A Novel Technique for Safer Pancreaticojejunostomy.
Konstadoulakis MM, Filippakis GM, Lagoudianakis E, Antonakis
PT, Dervenis C, Bramis J.
J Surg Oncol. 2005 Mar 15;89(4):268-72. Hippocration Hospital,
Athens Medical School, Greece.
[Link to Abstract]
Randomized Clinical Trial
of Pylorus-Preserving Duodenopancreatectomy Versus Classical
Whipple Resection -Long Term Results.
Seiler CA, Wagner M,
Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Buchler
MW.
Br J Surg. 2005 May;92(5):547-56. University of Berne, Inselspital,
Switzerland.
[Link to Abstract]
Synergistic Effects of Interferon-Alpha
in Combination with Chemoradiation on Human Pancreatic Adenocarcinoma.
Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW, Marten A.
World J Gastroenterol. 2005 Mar 14;11(10):1521-8. University
of Heidelberg, Germany.
[Link to Abstract]
FEBRUARY
Growth Inhibition of Human
Pancreatic Cancer Cells by Human Interferon-Beta Gene Combined
with Gemcitabine.
Endou M, Mizuno M, Nagata
T, Tsukada K, Nakahara N, Tsuno T, Osawa H, Kuno T, Fujita M,
Hatano M, Yoshida J.
Int J Mol Med. 2005 Feb;15(2):277-83. Toyama Medical and Pharmaceutical
University, Nagoya, Japan.
[Link to Abstract]
Growth Stimulation of COX-2-Negative
Pancreatic Cancer by a Selective COX-2 Inhibitor.
Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, Hines OJ.
Cancer Res. 2005 Feb 1;65(3):982-90. David Geffen School of Medicine
at University of California-Los Angeles.
[Link to Abstract]
A Pharmacological Study of
Celecoxib and Gemcitabine in Patients with Advanced Pancreatic
Cancer.
Xiong HQ, Plunkett W,
Wolff R, Du M, Lenzi R, Abbruzzese JL.
Cancer Chemother Pharmacol. 2005 Feb 22. University of Texas
/ MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Photodynamic Therapy for Pancreatic
and Biliary Tract Carcinoma.
Ayaru L, Bown SG, Pereira SP.
Int J Gastrointest Cancer. 2005;35(1):1-14. Royal Free &
University College London Medical School, England.
[Link to Abstract]
JANUARY
Homozygous Deletion of the
MTAP Gene in Invasive Adenocarcinoma of the Pancreas and in Periampullary
Cancer: A Potential New Target for Therapy.
Hustinx SR, Hruban RH,
Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Brown PN,
Argani P, Asfaq R, Fukushima N, Goggins M, Kern SE, Maitra A.
Cancer Biol Ther. 2005 Jan 15;4(1). Johns Hopkins Medical Institutions,
Baltimore, Maryland; Academic Medical Center, Amsterdam, Netherlands.
[Link to Abstract]
Phase I and Pharmacokinetic
Study of DE-310 in Patients with Advanced Solid Tumors.
Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA,
de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):703-11. Erasmus University
Medical Center, Rotterdam, Netherlands.
[Link to Abstract]
Quality of Life After Curative
or Palliative Surgical Treatment of Pancreatic and Periampullary
Carcinoma.
Nieveen van Dijkum EJ,
Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ.
Br J Surg. 2005 Jan 25. Academic Medical Centre, University of
Amsterdam, Netherlands.
[Link to Abstract]
Raltitrexed Plus Gemcitabine
(TOMGEM) in Advanced Pancreatic Cancer. Results of a Belgian
Multicentre Phase II Study.
Van Laethem JL, Van Maele P, Verslype C, Polus M, Demols A, Houbiers
G, Caenepeel P, Leleux A, Vermaut RR, Van Cutsem E, Peeters M.
Oncology. 2004;67(5-6):338-43. Erasme University Hospital, Brussels,
Belgium.
[Link to Abstract]
2004
DECEMBER
Efficacy of Selective Continuous
Transarterial Infusion Chemotherapy on Advanced Pancreatic Cancer.
Zhou JX, Hong GB, Xu
LY, Xu LF, Chen YT, Jiang RJ, Luo JH.
Ai Zheng. 2004 Dec;23(12):1677-80. Second Affiliated Hospital,
Sun Yat-sen University, Guangzhou, Guangdong, China.
[Link to Abstract]
Fluorouracil, Doxorubicin,
and Streptozocin in the Treatment of Patients with Locally Advanced
and Metastatic Pancreatic Endocrine Carcinomas.
Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R,
Yao JC.
J Clin Oncol. 2004 Dec 1;22(23):4762-71. University of Texas
/ M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Gemcitabine Versus FLEC Regimen
Given Intra-Arterially to Patients with Unresectable Pancreatic
Cancer: A Prospective, Randomized Phase III Trial of the Italian
Society for Integrated Locoregional Therapy in Oncology.
Cantore M, Fiorentini
G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo
C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C,
Marangolo M.
J Chemother. 2004 Dec;16(6):589-94. Oncological Department, USL
1, Massa and Carrara, Italy.
[Link to Abstract]
Isolated Hepatic Perfusion
for the Treatment of Patients with Advanced Liver Metastases
from Pancreatic and Gastrointestinal Neuroendocrine Neoplasms.
Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T,
Alexander HR Jr.
Surgery. 2004 Dec;136(6):1176-82. National Cancer Institute,
Bethesda, Maryland.
[Link to Abstract]
NOVEMBER
Curative Resection for a Pancreatic
Endocrine Carcinoma Involving the Portal Vein.
Sakamoto E, Hasegawa
H, Ogiso S, Igami T, Mori T, Mizuno T, Hattori K, Sugimoto M,
Fukami Y.
Hepatogastroenterology. 2004 Nov-Dec;51(60):1849-51. Nagoya Daini
Red Cross Hospital, Nagoya, Japan.
[Link to Abstract]
Laparoscopic Pancreatic Surgery
for Islet Cell Tumors of the Pancreas.
Assalia A, Gagner M.
World J Surg. 2004 Dec;28(12):1239-47. 2004 Nov 04. Weill Medical
College of Cornell University, New York-Presbyterian Hospital,
New York City.
[Link to Abstract]
A Randomized Multicenter Trial
Comparing Resection and Radiochemotherapy for Resectable Locally
Invasive Pancreatic Cancer.
Imamura M, Doi R, Imaizumi
T, Funakoshi A, Wakasugi H, Sunamura M, Ogata Y, Hishinuma S,
Asano T, Aikou T, Hosotani R, Maetani S.
Surgery. 2004 Nov;136(5):1003-11. Kyoto University, Japan.
[Link to Abstract]
Sequential and/or Concurrent
Hypofractionated Radiotherapy and Concurrent Chemotherapy in
Neoadjuvant Treatment of Advanced Adenocarcinoma of The Pancreas.
Outcome and Patterns of Failure.
Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P,
Siewert JR, Molls M, Jeremic B.
Hepatogastroenterology. 2004 Nov-Dec;51(60):1842-6. Technische
Universitaet Muenchen, Germany.
[Link to Abstract]
OCTOBER
Advances in the Genetic Screening,
Work-Up, and Treatment of Pancreatic Cancer.
Frucht H, Stevens PD,
Fogelman DR, Verna EC, Chen J, Chabot JA, Fine RL.
Curr Treat Options Gastroenterol. 2004 Oct;7(5):343-354. Columbia
University, New York City.
[Link to Abstract]
A Case of Successful Management
of Nonresectable Pancreas Cancer with Liver Metastasis by Intra-Arterial
Infusion Chemotherapy with Gemcitabine Hydrochloride, 5-FU, CDDP
and Administration of Tegafur/Uracil.
Ishikawa T, Mizuno K, Watanabe K, Baba Y, Oota H, Yoshida T,
Kamimura T.
Gan To Kagaku Ryoho. 2004 Oct;31(10):1555-8. Saiseikai Niigata
Second Hospital, Japan.
[Link to Abstract]
Phase I-II Trial of Twice-Weekly
Gemcitabine and Concomitant Irradiation in Patients Undergoing
Pancreaticoduodenectomy with Extended Lymphadenectomy for Locally
Advanced Pancreatic Cancer.
Joensuu TK, Kiviluoto
T, Karkkainen P, Vento P, Kivisaari L, Tenhunen M, Westberg R,
Elomaa I.
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52. Helsinki
University Central Hospital, Finland.
[Link to Abstract]
A Phase II Trial of FUdR in
Patients with Advanced Pancreatic Cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Oct;130(10):561-6. University of
Miami/Sylvester Comprehensive Cancer Center, Florida.
[Link to Abstract]
SEPTEMBER
Adjuvant Chemotherapy for
Unresectable Locally Advanced Pancreatic Cancer in Light of Its
Characteristics.
Taoka H, Hirano H, Mitsui
Y, Umino W, Nobuoka Y, Yamashita M, Tanigawa K, Yoshimine S,
Imai T, Kadowaki S, Miyashita K, Ikuma H, Nakamura T, Murata
T.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1365-70. HPB Interesting
Group, Suzuka General Hospital, Japan.
[Link to Abstract]
Antiangiogenic Versus Cytotoxic
Therapeutic Approaches to Human Pancreas Cancer: An Experimental
Study with a Vascular Endothelial Growth Factor Receptor-2 Tyrosine
Kinase Inhibitor and Gemcitabine.
Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito
I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del
Tacca M.
Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18. University of Pisa,
Pisa, Italy.
[Link to Abstract]
Isolated Roux-Loop Pancreaticojejunostomy:
A Series of 61 Patients with Zero Postoperative Pancreaticoenteric
Leaks.
Sutton CD, Garcea G,
White SA, O'Leary E, Marshall LJ, Berry DP, Dennison AR.
J Gastrointest Surg. 2004 Sep-Oct;8(6):701-5. Leicester General
Hospital, Leicester, England.
[Link to Abstract]
Phase I Study of a MUC1 Vaccine
Composed of Different Doses of MUC1 Peptide with SB-AS2 Adjuvant
in Resected and Locally Advanced Pancreatic Cancer.
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser
AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel
M, Finn OJ.
Cancer Immunol Immunother. 2004 Sep 14. University of Pittsburgh
Cancer Institute, Pittsburgh, Pennsylvania.
[Link to Abstract]
AUGUST
5-Fluorouracil-Based Chemoradiation
in Unresectable Pancreatic Carcinoma: Phase I-II Dose-Escalation
Study.
Morganti AG, Valentini
V, Macchia G, Mattiucci GC, Costamagna G, Deodato F, Smaniotto
D, Luzi S, Balducci M, Barbi S, Perri V, Trodella L, Cellini
N.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1454-60. Universita
Cattolica del S. Cuore, Campobasso, Italy.
[Link to Abstract]
Adjuvant Therapy in Pancreatic
Cancer: Phase I Trial of Radiation Dose Escalation with Concurrent
Full-Dose Gemcitabine.
Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D,
Brown D, Hejna G, Normolle D, Lawrence TS, McGinn CJ.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7. University
of Michigan School of Medicine, Ann Arbor, Michigan.
[Link to Abstract]
Neoadjuvant Chemoradiation
with Tegafur in Cancer of The Pancreas: Initial Analysis of Clinical
Tolerance and Outcome.
Calvo FA, Matute R, Garcia-Sabrido
JL, Gomez-Espi M, Martinez NE, Lozano MA, Herranz R.
Am J Clin Oncol. 2004 Aug;27(4):343-9. Hospital General Universitario
Gregorio Maranon, Madrid, Spain.
[Link to Abstract]
A Phase I Trial of The Dual
Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123
and Radiotherapy for Locally Advanced Pancreatic Cancer.
Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin
M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper
J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna
WG, Bernhard EJ, Hahn SM.
Clin Cancer Res. 2004 Aug 15;10(16):5447-54. University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania.
[Link to Abstract]
JULY
Cetuximab, a Monoclonal Antibody
Targeting the Epidermal Growth Factor Receptor, in Combination
with Gemcitabine for Advanced Pancreatic Cancer: A Multicenter
Phase II Trial.
Xiong HQ, Rosenberg A,
LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese
JL.
J Clin Oncol. 2004 Jul 1;22(13):2610-6. University of Texas /
M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Gefitinib ('Iressa', ZD1839),
A Selective Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitor, Inhibits Pancreatic Cancer Cell Growth, Invasion,
and Colony Formation.
Li J, Kleeff J, Giese N, Buchler MW, Korc M, Friess H.
Int J Oncol. 2004 Jul;25(1):203-10. University of Heidelberg,
Heidelberg, Germany.
[Link to Abstract]
A Phase II Trial of FudR in
Patients with Advanced Pancreatic Cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Jul 29. University of Miami / Sylvester
Comprehensive Cancer Center, Miami, Florida.
[Link to Abstract]
Pilot Study of Celecoxib and
Infusional 5-Fluorouracil as Second-Line Treatment for Advanced
Pancreatic Carcinoma.
Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini
P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F.
Cancer. 2004 Jul 1;101(1):133-8. Regina Elena National Cancer
Institute, Rome, Italy.
[Link to Abstract]
JUNE
A Case of Advanced Pancreatic
Cancer with Remarkable Response to Thalidomide, Celecoxib and
Gemcitabine.
Hada M, Mizutari K.
Gan To Kagaku Ryoho. 2004 Jun;31(6):959-61. Ashitaka Hospital,
Japan.
[Link to Abstract]
Gemcitabine Combined with
Infusional 5-Fluorouracil and High-Dose Leucovorin for The Treatment
of Advanced Carcinoma of The Pancreas.
Oztop I, Yilmaz U, Yavuzsen T, Yaren A, Tarhan O, Sagol O, Coker
A, Alakavuklar M.
Chemotherapy. 2004 Jun;50(3):127-32. University of Dokuz Eylul,
Izmir, Turkey.
[Link to Abstract]
Intensity-Modulated Radiotherapy
(IMRT) and Concurrent Capecitabine for Pancreatic Cancer.
Ben-Josef E, Shields
AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P,
Burmeister J, Bossenberger T, Philip PA.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9. Wayne State
University and the Karmanos Cancer Institute, Detroit, Michigan.
[Link to Abstract]
Intraductal Papillary Mucinous
Neoplasms of the Pancreas: An Updated Experience.
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell
KA, Lillemoe KD.
Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9. Johns Hopkins
Medical Institutions, Baltimore, Maryland.
[Link to Abstract]
MAY
5-Fluorouracil or Gemcitabine
Combined with Adenoviral-Mediated Reintroduction of P16ink4a
Greatly Enhanced Cytotoxicity in Panc-1 Pancreatic Adenocarcinoma
Cells.
Halloran CM, Ghaneh P,
Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello
E.
J Gene Med. 2004 May;6(5):514-25. Royal Liverpool University
Hospital, Liverpool, UK.
[Link to Abstract]
Fine Needle Aspiration Cytology
of Endocrine Neoplasms of The Pancreas. Morphologic and Immunocytochemical
Findings in 20 Cases.
Jimenez-Heffernan JA, Vicandi B, Lopez-Ferrer P, Gonzalez-Peramato
P, Perez-Campos A, Viguer JM.
Acta Cytol. 2004 May-Jun;48(3):295-301. Department of Pathology,
University Hospital, Guadalajara, Spain.
[Link to Abstract]
Islet Autotransplantation
Combined with Pancreatectomy for Treatment of Pancreatic Adenocarcinoma:
A Case Report.
Forster S, Liu X, Adam U, Schareck WD, Hopt UT.
Transplant Proc. 2004 May;36(4):1125-6. University of Rostock,
Germany; University of Freiburg, Germany.
[Link to Abstract]
Pancreaticoduodenectomy with
En Bloc Portal Vein Resection for Pancreatic Carcinoma with Suspected
Portal Vein Involvement.
Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong
J.
World J Surg. 2004, May 6. Queen Mary Hospital, University of
Hong Kong Medical Centre, China.
[Link to Abstract]
APRIL
Pancreatic Cancer Registry
in Japan: 20 Years of Experience.
Matsuno S, Egawa S, Fukuyama
S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H,
Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K.
Pancreas. 2004 Apr;28(3):219-30. Tohoku University Graduate School
of Medicine, Sendai, Japan.
[Link to Abstract]
Prospective Risk of Pancreatic
Cancer in Familial Pancreatic Cancer Kindreds.
Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus
GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH.
Cancer Res. 2004 Apr 1;64(7):2634-8. National Human Genome Research
Institute, NIH, Baltimore, Maryland.
[Link to Abstract]
Time Interval Between Abnormalities
Seen on CT and the Clinical Diagnosis of Pancreatic Cancer: Retrospective
Review of CT Scans Obtained Before Diagnosis.
Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS,
Crownhart BS, Chari ST.
AJR Am J Roentgenol. 2004 Apr;182(4):897-903. University of Medicine
and Dentistry of New Jersey, Newark, New Jersey.
[Link to Abstract]
|